异鼠李素抑制恶性肿瘤的机制研究进展

马文静; 刘婧纯; 雷文康; 伍先进; 赵若涵; 张健瑜; 胡敏

doi:10.14188/j.1671-8852.2026.0735

您当前的位置：

首页 >

文章列表页 >

异鼠李素抑制恶性肿瘤的机制研究进展

更新时间：2026-11-03

- 异鼠李素抑制恶性肿瘤的机制研究进展
- Advances in understanding the mechanisms of isorhamnetin⁃mediated inhibition of malignant tumors
- 武汉大学学报（医学版） 2026年页码：1-8
- 作者机构：
  
  1.武汉大学人民医院妇产科湖北武汉 430060
  2.武汉大学第一临床学院湖北武汉 430060
- 作者简介：
  
  马文静，女，2002—，医学硕士生，主要从事妇科肿瘤、复发性流产等相关机制研究，E⁃mail：mawenjing50@outlook.com。
  胡敏，E⁃mail：huminmmmmm@whu.edu.cn。
- 基金信息：
  
  国家自然科学基金青年科学基金项目（C类）(72404211;82504095);武汉市自然科学基金项目(2025040601020198);武汉大学人民医院交叉创新人才项目(JCRCGW⁃2022⁃008);中央高校基本科研业务费专项资金(2042025YXB010)
- DOI：10.14188/j.1671-8852.2026.0735
  中图分类号： R285
- 收稿：2026-05-08，
  
  网络首发：2026-11-03，
- 稿件说明：
移动端阅览
马文静, 刘婧纯, 雷文康, 等. 异鼠李素抑制恶性肿瘤的机制研究进展[J/OL]. 武汉大学学报（医学版）, 2026,1-8.

MA Wenjing, LIU Jingchun, LEI Wenkang, et al. Advances in understanding the mechanisms of isorhamnetin⁃mediated inhibition of malignant tumors[J/OL]. Medical Journal of Wuhan University, 2026, 1-8.
马文静, 刘婧纯, 雷文康, 等. 异鼠李素抑制恶性肿瘤的机制研究进展[J/OL]. 武汉大学学报（医学版）, 2026,1-8. DOI： 10.14188/j.1671-8852.2026.0735.

MA Wenjing, LIU Jingchun, LEI Wenkang, et al. Advances in understanding the mechanisms of isorhamnetin⁃mediated inhibition of malignant tumors[J/OL]. Medical Journal of Wuhan University, 2026, 1-8. DOI： 10.14188/j.1671-8852.2026.0735.

摘要

恶性肿瘤是人类面临的重大健康问题之一，目前已有许多除手术外的治疗方法，如免疫疗法、基因治疗等。异鼠李素（ISO）是一种来源于植物的天然活性成分，已被证实具有抗炎、抗肿瘤、抗氧化的作用。本文聚焦于其抗肿瘤作用，从机制层面出发，系统阐述ISO通过调控PI3K/AKT、MAPK等信号通路，及诱导细胞凋亡、阻滞细胞周期、抑制上皮间质转化等途径，显著抑制肿瘤进展。此外，研究表明ISO能够与部分化疗药物协同作用，增强治疗效果。然而目前其临床应用仍面临诸多限制，如水溶性低、体内代谢迅速等问题，这些仍是未来研究需要突破的关键挑战。

Abstract

Malignant tumors are one of the major health problems facing humanity. Currently

there are many therapeutic methods besides surgery

such as immunotherapy and gene therapy. Isorhamnetin is a natural active ingredient derived from plants

which has been proven to possess anti⁃inflammatory

anti⁃tumor

and antioxidant properties. This article focuses on its anti⁃tumor effects and systematically elaborates on how isorhamnetin significantly inhibits tumor progression at the mechanistic level. It achieves this by regulating signaling pathways such as PI3K/AKT and MAPK

as well as through inducing cell apoptosis

arresting the cell cycle

and inhibiting the epithelial⁃mesenchymal transition process. Furthermore

studies have shown that isorhamnetin can synergize with some chemotherapeutic drugs to enhance therapeutic efficacy. However

its clinical application still faces numerous limitations

such as low water solubility and rapid metabolism

in vivo

which remain key challenges to be addressed in future research.

关键词

Keywords

references

SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 ⁃ 249 .

KAUR R , BHARDWAJ A , GUPTA S . Cancer treatment therapies: Traditional to modern approaches to combat cancers [J ] . Mol Biol Rep , 2023 , 50 ( 11 ): 9663 ⁃ 9676 .

GONG G , GUAN Y Y , ZHANG Z L , et al . Isorhamnetin: A review of pharmacological effects [J ] . Biomed Pharmacother , 2020 , 128 : 110301 .

YANG B , LI X P , NI Y F , et al . Protective effect of isorhamnetin on lipopolysaccharide‑induced acute lung injury in mice [J ] . Inflammation , 2016 , 39 ( 1 ): 129 ⁃ 137 .

QI F , SUN J H , YAN J Q , et al . Anti‑inflammatory effects of isorhamnetin on LPS‑stimulated human gingival fibroblasts by activating Nrf2 signaling pathway [J ] . Microb Pathog , 2018 , 120 : 37 ⁃ 41 .

DUAN R , LIANG X , CHAI B D , et al . Isorhamnetin induces melanoma cell apoptosis via the PI3K/Akt and NF‑κB pathways [J ] . BioMed Res Int , 2020 , 2020 ( 1 ): 1057943 .

KIM D H , SUH J , SURH Y J , et al . Regulation of the tumor suppressor PTEN by natural anticancer compounds [J ] . Ann N Y Acad Sci , 2017 , 1401 ( 1 ): 136 ⁃ 149 .

HARWOOD M , DANIELEWSKA‑NIKIEL B , BORZELLECA J F , et al . A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties [J ] . Food Chem Toxicol , 2007 , 45 ( 11 ): 2179 ⁃ 2205 .

RASCIO F , SPADACCINO F , ROCCHETTI M T , et al . The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: An updated review [J ] . Cancers , 2021 , 13 ( 16 ): 3949 .

LEIPHRAKPAM P D , ARE C . PI3K/Akt/mTOR signaling pathway as a target for colorectal cancer treatment [J ] . Int J Mol Sci , 2024 , 25 ( 6 ): 3178 .

JIANG N N , DAI Q J , SU X R , et al . Role of PI3K/AKT pathway in cancer: The framework of malignant behavior [J ] . Mol Biol Rep , 2020 , 47 ( 6 ): 4587 ⁃ 4629 .

LI C H , LI J W , LI Y , et al . Isorhamnetin promotes MKN⁃45 gastric cancer cell apoptosis by inhibiting PI3K‑mediated adaptive autophagy in a hypoxic environment [J ] . J Agric Food Chem , 2021 , 69 ( 29 ): 8130 ‑ 8143 .

ZHAI T Y , ZHANG X Y , HEI Z Y , et al . Isorhamnetin inhibits human gallbladder cancer cell proliferation and metastasis via PI3K/AKT signaling pathway inactivation [J ] . Front Pharmacol , 2021 , 12 : 628621 .

孙同同 , 张栋栋 , 张堃 , 等 . 异鼠李素对人卵巢癌作用机制 [J ] . 山东第一医科大学(山东省医学科学院)学报 , 2024 , 45 ( 1 ): 7 ⁃ 12 .

SUN T T , ZHANG D D , ZHANG K , et al . The mechanism of action of isorhamnetin on human ovarian cancer [J ] . J Shandong First Med Univ Shandong Acad Med Sci , 2024 , 45 ( 1 ): 7 ⁃ 12 .

ZHANG P , SUN Y S , SHI L , et al . Effect of isorhamnetin on carbonic anhydrase Ⅸ expression and tumorigenesis of bladder cancer by activating PPARγ/PTEN/AKT pathway [J ] . Tissue Cell , 2023 , 82 : 102048 .

KIM E K , CHOI E J . Compromised MAPK signaling in human diseases: An update [J ] . Arch Toxicol , 2015 , 89 ( 6 ): 867 ⁃ 882 .

CHAKRABORTY J , CHAKRABORTY S , CHAKRABORTY S , et al . Entanglement of MAPK pathways with gene expression and its omnipresence in the etiology for cancer and neurodegenerative disorders [J ] . Biochim Biophys Acta Gene Regul Mech , 2023 , 1866 ( 4 ): 194988 .

SHI X F , YU Q , WANG K B , et al . Active ingredients Isorhamnetin of Croci Srigma inhibit stomach adenocarcinomas progression by MAPK/mTOR signaling pathway [J ] . Sci Rep , 2023 , 13 ( 1 ): 12607 .

CHEN Q , SONG S J , WANG Z , et al . Isorhamnetin induces the paraptotic cell death through ROS and the ERK/MAPK pathway in OSCC cells [J ] . Oral Dis , 2021 , 27 ( 2 ): 240 ⁃ 250 .

SUGIURA R , SATOH R , TAKASAKI T . ERK: A double⁃edged sword in cancer. ERK‑dependent apoptosis as a potential therapeutic strategy for cancer [J ] . Cells , 2021 , 10 ( 10 ): 2509 .

SHIN S , BUEL G R , WOLGAMOTT L , et al . ERK2 mediates metabolic stress response to regulate cell fate [J ] . Mol Cell , 2015 , 59 ( 3 ): 382 ⁃ 398 .

HU S , HUANG L M , MENG L W , et al . Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen⁃activated protein kinase kinase signaling pathways [J ] . Mol Med Rep , 2015 , 12 ( 5 ): 6745 ⁃ 6751 .

WANG J L , QUAN Q H , JI R F , et al . Isorhamnetin suppresses PANC⁃1 pancreatic cancer cell proliferation through S phase arrest [J ] . Biomed Pharmacother , 2018 , 108 : 925 ⁃ 933 .

DESCHÊNES⁃SIMARD X , MALLESHAIAH M , FERBEYRE G . Extracellular signal‑regulated kinases: one pathway, multiple fates [J ] . Cancers , 2024 , 16 ( 1 ): 95 .

YANG T S , XIAO Y , LIU S , et al . Isorhamnetin induces cell cycle arrest and apoptosis by triggering DNA damage and regulating the AMPK/mTOR/p70S6K signaling pathway in doxorubicin⁃resistant breast cancer [J ] . Phytomedicine , 2023 , 114 : 154780 .

刘媛媛 , 邰国梅 . 异鼠李素调节p62‑Keap1‑Nrf2信号通路对食管癌细胞增殖、侵袭及凋亡的影响 [J ] . 解剖学杂志 , 2025 , 48 ( 5 ): 412 ‑ 416 .

LIU Y Y , TAI G M . Effects of isorhamnetin on proliferation, invasion, and apoptosis of esophageal cancer cells by regulating the p62⁃Keap1⁃Nrf2 signaling pathway [J ] . Chin J Anat , 2025 , 48 ( 5 ): 412 ‑ 416 .

RANA J N , GUL K , MUMTAZ S . Isorhamnetin: Reviewing recent developments in anticancer mechanisms and nanoformulation⁃driven delivery [J ] . Int J Mol Sci , 2025 , 26 ( 15 ): 7381 .

LUO W , LIU Q B , JIANG N , et al . Isorhamnetin inhibited migration and invasion via suppression of Akt/ERK⁃mediated epithelial⁃to⁃mesenchymal transition (EMT) in A549 human non‑small‑cell lung cancer cells [J ] . Biosci Rep , 2019 , 39 ( 9 ): BSR20190159 .

LI C L , YANG D , ZHAO Y W , et al . Inhibitory effects of isorhamnetin on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase⁃2/9 [J ] . Nutr Cancer , 2015 , 67 ( 7 ): 1191 ⁃ 1200 .

PARK C , CHA H J , CHOI E O , et al . Isorhamnetin induces cell cycle arrest and apoptosis via reactive oxygen species⁃mediated AMP⁃activated protein kinase signaling pathway activation in human bladder cancer cells [J ] . Cancers , 2019 , 11 ( 10 ): 1494 .

WANG M M , XU Z T , CAI Q , et al . Isorhamnetin inhibits progression of ovarian cancer by targeting ESR1 [J ] . Ann Transl Med , 2022 , 10 ( 22 ): 1216 .

LI Q , REN F Q , YANG C L , et al . Anti‑proliferation effects of isorhamnetin on lung cancer cells in vitro and in vivo [J ] . Asian Pac J Cancer Prev , 2015 , 16 ( 7 ): 3035 ⁃ 3042 .

MANU K A , SHANMUGAM M K , RAMACHANDRAN L , et al . Isorhamnetin augments the anti⁃tumor effect of capeciatbine through the negative regulation of NF⁃κB signaling cascade in gastric cancer [J ] . Cancer Lett , 2015 , 363 ( 1 ): 28 ⁃ 36 .

TAN Z G , LIU J , HOU M , et al . Isorhamnetin inhibits cholangiocarcinoma proliferation and metastasis via PI3K/AKT signaling pathway [J ] . Discov Oncol , 2025 , 16 ( 1 ): 469 .

SARKAR S , DAS A K , BHATTACHARYA S , et al . Isorhamnetin exerts anti⁃tumor activity in DEN+CCl 4 ⁃induced HCC mice [J ] . Med Oncol , 2023 , 40 ( 7 ): 188 .

ZHANG B Y , WANG Y M , GONG H , et al . Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cisplatin and carboplatin in non⁃small cell lung carcinoma (NSCLC) [J ] . Int J Clin Exp Pathol , 2015 , 8 ( 1 ): 25 ⁃ 37 .

GENTA S , MARTORANA F , STATHIS A , et al . Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment [J ] . Crit Rev Oncol Hematol , 2021 , 168 : 103539 .

ABD‑ELLATEF G E F , GAZZANO E , EL‑DESOKY A H , et al . Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P⁃glycoprotein [J ] . Pharmacol Res , 2022 , 175 : 105975 .

TAN W L , LUO X , LI W D , et al . TNF⁃α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma [J ] . EBioMedicine , 2019 , 40 : 446 ‑ 456 .

刘鸿辉 . 异鼠李素靶向FHL2/β⁃catenin轴调控胰腺癌进展及化疗增敏的机制研究 [D ] . 长沙 : 中南大学 , 2025 .

LIU H H . Study on the mechanism of isorhamnetin targeting the FHL2/β⁃catenin axis to regulate pancreatic cancer progression and chemosensitization [D ] . Changsha : Central South University , 2025 .

HU J J , ZHANG Y H , JIANG X X , et al . ROS⁃mediated activation and mitochondrial translocation of CaMKⅡ contributes to Drp1⁃dependent mitochondrial fission and apoptosis in triple⁃negative breast cancer cells by isorhamnetin and chloroquine [J ] . J Exp Clin Cancer Res , 2019 , 38 ( 1 ): 225 .

范东伟 , 陈本鑫 , 余有声 , 等 . 异鼠李素靶向CYP1B1/NF⁃κB信号抑制乳腺癌进展并增强紫杉醇敏感性的机制研究 [J ] . 西安交通大学学报(医学版) , 2025 , 46 ( 5 ): 842 ⁃ 851 .

FAN D W , CHEN B X , YU Y S , et al . Isorhamnetin mediates CYP1B1/NF⁃κB signaling to inhibit breast cancer progression and enhance paclitaxel sensitivity [J ] . J Xi'an Jiaotong Univ Med Sci , 2025 , 46 ( 5 ): 842 ‑ 851 .

ABUDALO R , GAMMOH O , ALTABER S , et al . Mitigation of cisplatin⁃induced cardiotoxicity by Isorhamnetin: Mechanistic insights into oxidative stress, inflammation, and apoptosis modulation [J ] . Toxicol Rep , 2024 , 12 : 564 ⁃ 573 .

SUN J , SUN G B , MENG X B , et al . Isorhamnetin protects against doxorubicin⁃induced cardiotoxicity in vivo and in vitro [J ] . PLoS One , 2013 , 8 ( 5 ): e64526 .

DU Y R , JIA C , LIU Y , et al . Isorhamnetin enhances the radiosensitivity of A549 cells through interleukin⁃13 and the NF‑κB signaling pathway [J ] . Front Pharmacol , 2020 , 11 : 610772 .

PAN Y K , LI R , JING N N , et al . Isorhamnetin⁃lignin nanoparticles: Green preparation, characterization, remarkable bioavailability and long⁃lasting bioactivity in vivo [J ] . Food Biosci , 2025 , 69 : 106931 .

ZHAO J J , YANG J , XIE Y . Improvement strategies for the oral bioavailability of poorly water⁃soluble flavonoids: An overview [J ] . Int J Pharm , 2019 , 570 : 118642 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

特发性血小板减少性紫癜患者T细胞周期和促凋亡蛋白Caspase-3表达的变化

柚皮素对人髓系白血病K562细胞增殖的作用

苦参碱诱导血管紧张素Ⅱ作用的心肌成纤维细胞凋亡

CUL7通过泛素化降解MST1抑制头颈鳞状细胞癌细胞凋亡

毛蕊花苷通过调节PPARα减轻心肌细胞缺氧复氧损伤